-
Mashup Score: 3ESMO-MCBS Scorecards - 11 month(s) ago
ESMO is Europe’s leading medical oncology society, providing a professional network for its members and working with national societies across Europe.
Source: www.esmo.orgCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 4Clinical Trials Register - 11 month(s) ago
E.1 Medical condition or disease under investigation E.1.1Medical condition(s) being investigated Adult male or female patients scheduled for ICT with metastasized or irresectable melanoma E.1.1.1Medical condition in easily understood language E.1.1.2Therapeutic area Diseases [C] – Cancer [C04] MedDRA Classification E.1.2 Medical condition or disease under…
Source: www.clinicaltrialsregister.euCategories: Latest Headlines, Oncologists1Tweet-
We are currently investigating the use of #ImmunoPET w/ crefmirlimab, a radiolabelled human CD8-targeting minibody, in pts with inoperable #stage III/IV #melanoma treated w/ #nivoipi If you want to know more about it, drop us a line!📩 https://t.co/7tlO9hKp5L #immunotherapy https://t.co/Lh0viJBi24 https://t.co/ayDZjW9fEF
-
-
Mashup Score: 5Towards evidence-based response criteria for cancer immunotherapy - Nature Communications - 12 month(s) ago
Early detection of immunotherapy-induced tumor response is of major benefit for patients but can be complicated by therapy-induced pseudoprogression. A consensus guideline-iRECIST- was developed as a modification of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1). Here we describe which next steps are required to test its validity and how novel approaches for response criteria…
Source: NatureCategories: Latest Headlines, Oncologists1Tweet-
RT @VriesElisabeth: potential next steps for RECIST @ElenaGarralda @LSeymourMD @NatureComms https://t.co/lZA06NpesG
-
-
Mashup Score: 019. Tübinger Symposium Dermatologische Onkologie am 20.05.2023 | Universitätsklinikum Tübingen - 12 month(s) ago
19. Tübinger Symposium Dermatologische Onkologie am 20.05.2023 Update zu Therapiemöglichkeiten beim Melanom, Plattenepithelkarzinom und Neues zur Chirurgie dermatoonkologischer Tumore Bei nahezu allen dermatologischen Tumoren gibt es neue, wichtige therapeutische Optionen. Die diesjährigen Schwerpunkte sind:• Systemtherapie beim Melanom im…
Source: www.medizin.uni-tuebingen.deCategories: Latest Headlines, Oncologists1Tweet-
There is still time to join us for the annual Dermato-oncology Symposium on Saturday. Participation is free of charge - You just need to send us an email ‼️💯More information in the link https://t.co/Oy5FN3n6lo #Oncology #melanoma #skincancerawarenessmonth https://t.co/SUclMpmGYF
-
-
Mashup Score: 2Neoadjuvant immunotherapy for melanoma is now ready for clinical practice - Nature Medicine - 12 month(s) ago
Individuals with cutaneous melanoma who are treated with neoadjuvant immunotherapy show a substantial improvement; this should be incorporated into standard care.
Source: NatureCategories: Latest Headlines, Oncologists1Tweet-
#neoadjuvant #immunotherapy for #melanoma ready for clinical practice @NatureMedicine @PAscierto @ProfGLongMIA @DrSapnaPatel @HTawbi_MD @amenzies9 @ProfRScolyerMIA @MandalaMario #SkinCancerAwarenessMonth https://t.co/D3xDE6VFcT https://t.co/MvIgVjodHb
-
-
Mashup Score: 7It matters who does science - 1 year(s) ago
Scientific research is a social process that occurs over time with many minds contributing. But the public has been taught that scientific insight occurs when old white guys with facial hair get hit on the head with an apple or go running out of bathtubs shouting “Eureka!” That’s not how it works, and it never has been. Rather, scientists work in teams, and those teams share findings with other…
Source: www.science.orgCategories: Latest Headlines, Oncologists1Tweet-
RT @ReiseSousaLab: Read this. Worth 5 minutes of your time. It matters who does science https://t.co/fpBVRZKhW8
-
-
Mashup Score: 1ESMO Guidelines Committee - 1 year(s) ago
The ESMO Guidelines Committee and Guidelines Steering Committee manage the ESMO Clinical Practice Guidelines & related products/activities.
Source: www.esmo.orgCategories: Latest Headlines, Oncologists1Tweet-
Always a good time for good news! #May is #SkinCancerAwarenessMonth & am I sharing with you the tremendous honor of having been nominated #subjecteditor of @myESMO clinical practice #guidelines for #melanoma & #skincancers https://t.co/gAMZ6IWyPr Thank you, #ESMO https://t.co/64iLJXavbD
-
-
Mashup Score: 0ESMO Congress 2023: Abstracts - 1 year(s) ago
The abstract submission system is now open!
Source: www.esmo.orgCategories: Latest Headlines, Oncologists1Tweet-
This year, I have the honor & privilege to be #chair of the @myESMO #esmo2023 congress for #melanoma & other #skinCancers track. ‼️You still have time 2 submit your #research in this and other areas. ⏳️Deadline in 10.05! We are all looking forward to it. https://t.co/5UKEfKC95f https://t.co/ZooEjDTalO
-
-
Mashup Score: 4
The Angeles Clinic and Research Institute The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, has established an international reputation for developing new cancer therapies, providing the best in experimental and traditional treatments, and expertly guiding and training the next generation of clinicians. Date: Saturday – May 6, 2023 Time: 12:00 PM (ET)| 11:00 AM (CT) | 10:00 AM…
Source: AIM at Melanoma FoundationCategories: Latest Headlines, Oncologists1Tweet-
RT @OmidHamidMD: #MelanomaMonday #melanoma awareness month - great speakers, major striddes.... https://t.co/eJ4X1ozNBm https://t.co/JScYi…
-
-
Mashup Score: 0ESMO Congress 2023: Abstracts - 1 year(s) ago
The abstract submission system is now open!
Source: www.esmo.orgCategories: Latest Headlines, Oncologists1Tweet-
Are U planning 2 submit an abstract 2 #ESMO23 ? ⏳10.05 ‼️ https://t.co/5UKEfKCGUN The super faculty #Melanoma & #skintumors track looks forward to your submissions! Ryan Sullivan Caroline Robert Teresa Petrella Dirk Schadendorf Boris Bastian Alexander van Akkooi Reinhard Dummer https://t.co/rXoHIqqokS
-
RT @GPentheroudakis: Great ESMO MCBS Visualisations at https://t.co/sHEV2Oix2K https://t.co/8RyDsV4J1M